Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone513-579-9911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$704.59 million
Profitability
Miscellaneous
Employees2,900
Next Earnings Date10/28/2019 (Confirmed)
OptionableOptionable
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings data on Monday, July, 29th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.63 by $0.18. The business had revenue of $214.10 million for the quarter, compared to analyst estimates of $200.99 million. Medpace had a return on equity of 17.65% and a net margin of 11.28%. The business's revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.61 earnings per share. View Medpace's Earnings History.
When is Medpace's next earnings date?
How can I listen to Medpace's earnings call?
Medpace will be holding an earnings conference call on Monday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Medpace issued on next quarter's earnings?
Medpace updated its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of $2.83-2.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.65. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $827.58 million.
What price target have analysts set for MEDP?
4 Wall Street analysts have issued 1-year price objectives for Medpace's stock. Their predictions range from $62.00 to $85.00. On average, they anticipate Medpace's stock price to reach $74.67 in the next twelve months. This suggests that the stock has a possible downside of 5.0%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.
Has Medpace been receiving favorable news coverage?
Media coverage about MEDP stock has been trending very negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medpace earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Medpace.
Are investors shorting Medpace?
Medpace saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 2,320,000 shares, a decrease of 12.8% from the August 15th total of 2,660,000 shares. Based on an average trading volume of 407,200 shares, the days-to-cover ratio is currently 5.7 days. Currently, 8.5% of the shares of the stock are sold short. View Medpace's Current Options Chain.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of Medpace own?
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by a number of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.54%), Scout Investments Inc. (0.27%), Envestnet Asset Management Inc. (0.07%), Bowling Portfolio Management LLC (0.06%), CIBC Private Wealth Group LLC (0.06%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Tributary Capital Management LLC, Optimum Investment Advisors, Bowling Portfolio Management LLC, Envestnet Asset Management Inc. and Crossmark Global Holdings Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was bought by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Navellier & Associates Inc, We Are One Seven LLC, Cim LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $78.57.
How big of a company is Medpace?
Medpace has a market capitalization of $2.82 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
